Italy lifts ban on Novartis flu vaccines

Italian health authorities on Friday lifted a ban on the sale of flu vaccines made by Swiss pharmaceutical giant Novartis, saying that tests had shown they were not a health risk.

"The decision was made possible due to in-depth checks which were carried out as a precaution to protect public health," Italy's public agency for pharmaceuticals AIFA said in a statement.

Italy's health ministry last month ordered a ban on Aggripal, Fluad and Influpozzi after white particles were seen in syringes carrying the vaccines.

Austria, Canada, Germany and Switzerland subsequently also ordered temporary bans although some have since been lifted.

Novartis has said it is confident on the "safety and efficacy" of its vaccines.

add to favorites email to friend print save as pdf

Related Stories

Germany orders recall of some Novartis flu shots

Oct 25, 2012

(AP)—German authorities ordered a recall Thursday of some batches of Novartis flu vaccine as a precautionary measure after the company reported the appearance of small particles in the manufacturing process.

EU drug agency: License 2 swine flu vaccines

Sep 25, 2009

(AP) -- The European Union's drug regulator recommended Friday that two swine flu vaccines be licensed in the 27-nation bloc to ensure their availability before the start of the normal flu season.

Recommended for you

Expression of privilege in vaccine refusal

19 hours ago

Not all students returning to school this month will be up to date on their vaccinations. A new study conducted by Jennifer Reich, a researcher at the University of Colorado Denver, shows that the reasons why children may ...

Using computers to design drugs

Aug 22, 2014

Designing a new medicine is an expensive and time consuming business. Typically it takes around $2 billion and ten years for a new drug to move from its initial design in the lab, to the clinic. All the ...

Lilly psoriasis drug fares well in late-stage test

Aug 22, 2014

Drugmaker Eli Lilly and Co. said its potential psoriasis treatment fared better than both a fake drug and a competitor's product during late-stage testing on patients with the most common form of the skin disease.

User comments